Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs

This weight loss option beats Ozempic by 5 times

Bariatric surgery far outperformed GLP-1 weight loss drugs in a new real-world comparison of more than 50,000 patients. Two years after treatment, surgery patients lost about 58 pounds on average, while those using semaglutide or tirzepatide lost roughly 12 pounds. Even patients who stayed on GLP-1 drugs for a full year saw much smaller results than surgical patients. High dropout rates and real-world challenges appear to blunt the drugs’ effect…

Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

Bariatric surgery significantly more effective than GLP-1 drugs for weight loss and disease remission, review finds

Metabolic and bariatric surgery delivers significantly greater weight loss and higher rates of obesity-related disease remission than glucagon-like peptide-1 receptor agonists (GLP-1s), according to one of the largest and most comprehensive real-world comparisons of the two treatments. The findings were presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting (ASMBS2026).

Gut Microbiota Changes Link to Diabetes Remission Post-Surgery

In the rapidly evolving field of metabolic health, a groundbreaking study published in Nature Metabolism sheds new light on the profound impact of bariatric surgery on the gut microbiota and its intricate association with metabolic improvements and type 2 diabetes remission. This research, led by Olsson, Borgeraas, Chakaroun, and colleagues, meticulously explores how alterations in […]

Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition space

New Delhi, May 7 (PTI) Dr Reddy's and Nestle Health Science Ltd on Thursday announced strengthening of presence in diabetes and obesity nutrition space with the launch of 'Celevida GLP+'. The company, a joint venture between Dr Reddy's Laboratories and Nestle India Ltd, said Celevida GLP+ is a specialised scientifically designed product to support optimum nutrition intake and muscle mass maintenance for sustaining metabolic and functional healt…